Drug intelligence / Profile preview

RV2666C + LA2984

Development stage: Preclinical
Lead developer: Pierre Fabre
Administration: Topical

Overview

RV2666C + LA2984 is a combination drug consisting of two separate investigational agents, RV2666C and LA2984. Its formulation is under evaluation in clinical trials, and each compound is administered sequentially to different participant groups. The specific mechanisms of action, molecular targets, indications, developers, and exact composition of both RV2666C and LA2984 are not disclosed in public sources. The combination represents a strategy to test additive or synergistic effects of multiple agents, common in early-phase therapeutic development[2].

Beyond the preview

Go deeper on RV2666C + LA2984.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RV2666C + LA2984.

Explore the full profile